RxDoctor Payments Data

Roger Lo, MD

Dermatology · Los Angeles, CANPI 1326070657

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,000 of the $2,866 with a category attached, or 69.8%. Array Biopharma Inc accounts for 69.8% of it on its own, with 1 other manufacturer making up the rest.

$2,866in general payments, 2019–2025

Across 2 payments — averaging $1433.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Array Biopharma Inc$2K
  • AstraZeneca$866
$724,441in research payments, 2019–2025

Across 7 payments — averaging $103,492 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Array Biopharma Inc$351K
  • Pfizer$161K
  • Merck$155K
  • Day One Biopharmaceuticals$58K

What the payments were for

  • Consulting fees$2,00070%
  • Charitable contribution$86630%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Array Biopharma Inc1$2,000
AstraZeneca1$866

How this compares

$2,866 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$3,552
Medicare patients
20
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →